期刊文献+

英夫利昔单抗治疗强直性脊柱炎累及颞颌关节一例 被引量:1

原文传递
导出
摘要 患者男,41岁,以"腰骶部疼痛僵直二十余年,伴张口困难1个月",门诊以"强直性脊柱炎"收住兰州大学第二医院疼痛科。患者于二十余年前出现腰骶部疼痛,并间断出现双膝、双髋、双踝关节肿痛,夜间痛明显,晨僵约2h,发病过程中曾有足跟痛,发生过一次眼炎,无腹泻史,未经过正规治疗(具体方案不详)。近1个月腰骶部疼痛加重,双膝关节肿痛,双髋关节疼痛,张口困难,咬合疼痛,进食困难。专科查体:生命体征平稳,跛行,支具行走,双膝关节肿胀,压痛,浮髌试验(+)。
出处 《中华临床医师杂志(电子版)》 CAS 2011年第7期2162-2163,共2页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献10

  • 1张胜桃,隗佳,何培根.生物制剂在类风湿关节炎的临床应用[J].中华临床医师杂志(电子版),2010,4(2):1-3. 被引量:8
  • 2Benazzou S,Maagoul R,Boulaadas M,et al.Ankylosis of the temporomandibular joint:a rare manifestation of ankylosing spondylitis. Revue de Stomatologie et de Chirurgie Maxillo Faciale . 2005
  • 3EinaudI G,Viara M.Research on the behavior of the temporomandibular joint in patients affected by ankylosing spondylitis. Reumatizam . 1964
  • 4Braun J,Deodhar A,Dijkmans B,et al.Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis and Rheumatism . 2008
  • 5Gleissner C,Kaesser U,Dehne F,et al.Temporomandibular joint function in patients with longstanding rheumatoid arthritis-I.Role of periodontal status and prosthetic care-A clinical study. European Journal of Medical Research . 2003
  • 6L.M.J.Helenius,P.Tervahartiala,I.Helenius,et al.Clinical,radiographic and MRI findings of the temporo-mandibular joint in patients with different rheumatic diseases. Int.J.Oral Maxillofac.Surg . 2006
  • 7Major P,Ramos-Remus C,Suarez-Almazor ME.Magnetic resonance imaging and clinical assessment of temporomandibular joint pathology in ankylosing spondylitis. The Journal of Rheumatology . 1999
  • 8Ramos-Remus C,Perez-Rocha O,Ludwig RN,et al.Magnetic resonance changes in the temporomandibular joint in ankylosing spondylitis. The Journal of Rheumatology . 1997
  • 9HAIBEL H,SIEPER J.Editorial review:how earlyshould ankylosing spondylitis be treated with a tumornecrosis factor-blocker?. Current Opinion in Rheumatology . 2010
  • 10X Baraliakos,J Listing,M Rudwaleit.Safety and efficacy of readministration of infliximab after long term continuous therapy and withdrawal in patients with ankylosing spondylitis. The Journal of Rheumatology . 2007

二级参考文献10

  • 1Yazici Y,,Shi N,John A.Utilization of biologic agents in rheumatoid arthritis in the United States:analysis of prescribing patterns in16,752newly diagnosed patients and patients new to biologic therapy[].Bull NYUHosp Jt Dis.2008
  • 2Nurmohamed MT,Dijkmans BA.Are biologics more effective than classical disease-modifying antirheumatic drugs[].Arthritis Research and Therapy.2008
  • 3Alonso-Ruiz A,Pijoan JI,Ansuategui E,et al.Tumor necrosis factor alpha drugs in rheumatoid arthritis:systematic review and metaanalysis of efficacy and safety[].BMC Musculoskeletal Disorders.2008
  • 4Bongartz T,Sutton AJ,Sweeting MJ,et al.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials[].Journal of the American Medical Association The.2006
  • 5DONAHUE KE,GARTLEHNER G,JONAS DE,et al.Systematic review:comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis[].Annals of Internal Medicine.2008
  • 6Alonso-Ruiz A,Pijoan JI,Ansuategui E,et al.Tumor necrosis factor alpha drugs in rheumatoid arthritis:systematic review and metaanalysis of efficacy and safety[].BMC Musculoskeletal Disorders.2008
  • 7Goekoop-Ruiterman YP,de Vries-Bouwstra JK,Allaart CF,et al.Comparison of treatment strategies in early rheumatoid arthri-tis:a randomized trial[].Annals of Internal Medicine.2007
  • 8James R O’Dell.The BeSt Way to Treat Early Rheumatoid Arthritis?[].Annals of Internal Medicine.2007
  • 9Sfriso P,Salaffi F,Montecucco CM,et al.MonitorNet:the Italian multicentre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice[].Reumatizam.2009
  • 10Fabiola Atzeni,Marco Antivalle,Francesca Bobbio Pallavicini,et al.Predicting response to anti-TNF treatment in rheumatoid arthritis pa-tients[].Autoimmu Rev.2009

共引文献7

同被引文献54

  • 1Markham A, Lamb H M. Inflximab:a new of its use in the management of rheumatoid arthritis [ J I. Drugs,2000, 59 (6) : 1341 - 1359.
  • 2Smolen J S,Aletaha D, Bijlsma J W,et aL Treating rheumatoid arthritis to target:recommendations of an international task force [ J ]. Ann Rheum Dis,2010,69(4) :631 -637.
  • 3Scheinberg M, Goldenberg J,Feldman D P, et al. Retrospective study e- valuating dose standards for infliximah in patients with rheumatoid arthri- tis at Hospital Israelita Albert Einstein, Sao Paulo, Brazil[ J ]. Clin Rheu- mato1,2008,27 ( 8 ) : 1049 - 1052.
  • 4Elliott M J, Maini R N, Feldmann M, et al. Treatment of rheumatoid ar- thritis with chimeric monoclonal antibodies to tumor necrosis factor alpha [ J 1. Arthritis Rheum, 1993,36 ( 12 ) : 1681 - 1690.
  • 5Pieringer H, Stuby U, Pohanka E, et al. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with inflix- imab[ J]. Clin Rheumato1,2010,29 (7) :723 -727.
  • 6Smolen J S, van Der Heijde D M, St Clair E W, et al. Active - controlled study of patients receiving infliximab for the treatment of rheumatoid ar- thritis of early onset(ASPIRE) study group. Predietors of joint damage in patients with early rheumatoid arthritis treated with high - dose metho- trexate with or without concomitant infliximab : results from the ASPIRE trialC J. Arthritis Rheum,2006, 54(3 ) :702 - 710.
  • 7Allaart C F, Goekoop - Ruiterman Y P, de Vries - Beuwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combi- nation therapy or initial monotherapy strategies:the BeSt study [ J ]. Clin Exp Rheumatol,2006,24(s6) :77 -82.
  • 8Furst D E, Gaylis N, Bray V, et al. Open - label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete re- sponse to etanereept :the opposite study[ J ]. Ann Rheum Dis,2007, 66 (7) :893 -899.
  • 9Kanbe K, Inoue K, Inoue Y, et al. Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheuma- toid arthritis[ J]. Clin Rheumato1,2008,27 ( 6 ) :777 - 781.
  • 10Takeuchi T, Yamanaka H, Inoue E ,et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheuma- toid arthritis management group in Japan: one - year outcome of joint destruction ( RECONFIRM - 2J) [ J]. Mod Rheumatol, 2008,18 ( 5 ) : 447 - 454.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部